Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study

NCT07174141 · clinicaltrials.gov ↗

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Treatment With Second-generation Bruton's Tyrosine Kinase Inhibitors (Acalabrutinib, Zanubrutinib)

Interventions

OTHER: Ophthalmological examination
BIOLOGICAL: Blood sample

Sponsor

Centre Hospitalier Universitaire Dijon